Multicenter, retrospective cohort study of antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacterium infections in the United States
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01596-24 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Michael P Veve und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Henry Ford Hospital, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Mycobacterium Infections, Nontuberculous, Nontuberculous Mycobacteria. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Paratek Pharmaceuticals.
Abstract (Originalsprache)
Non-tuberculosis mycobacteria (NTM) are extensively drug-resistant organisms that require long-term therapy. The study purpose was to quantify the incidence of and risk factors for antimycobacterial-associated adverse drug events (ADEs) in persons with NTM infections receiving outpatient therapy. A multicenter, retrospective cohort was performed of persons with NTM infections who received antimycobacterial treatment from 2013 to 2024. Inclusion criteria were age ≥18 years, ≥1 month of outpatient treatment, and ≥1 follow-up outpatient visit within 3 months of index encounter. Mycobacterium avium complex and Mycobacterium tuberculosis complex were excluded. The primary outcome was development of pre-specified treatment-related ADE or acute kidney injury (AKI), thrombocytopenia, and/or Clostridioides difficile infection (CDI) through 12 months of therapy. Secondary outcomes included therapy discontinuation due to any treatment-related ADEs. Two hundred patients were included: 14% developed a pre-specified ADE. Mycobacterium abscessus (29%) was the most common pathogen; most initial regimens included a macrolide (54%), systemic aminoglycoside (24%), β-lactam (24%), or tetracycline derivative (22%). The most common pre-specified ADEs were thrombocytopenia (9%), AKI (8%), and CDI (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Henry Ford Hospital, Detroit, Michigan, USA.
- Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
- Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA.
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.
ORCID-Profile: Michael P Veve
Förderung
- Paratek Pharmaceuticals
Zitieren
APA
Veve, M. P., Kenney, R. M., Aljundi, A. M., Dierker, M. S., Athans, V., Shallal, A. B., & Patel, N. (2025). Multicenter, retrospective cohort study of antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacterium infections in the United States. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01596-24
Vancouver
Veve MP, Kenney RM, Aljundi AM, Dierker MS, Athans V, Shallal AB, et al. Multicenter, retrospective cohort study of antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacterium infections in the United States. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01596-24
BibTeX
@article{Veve2025,
author = {Veve, Michael P and Kenney, Rachel M and Aljundi, Alisar M and Dierker, Michelle S and Athans, Vasilios and Shallal, Anita B and Patel, Nimish},
title = {Multicenter, retrospective cohort study of antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacterium infections in the United States},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01596-24}
}
EUVIMED